quarter for product first I potential future about day helm you call. the on joining I And my us joined. Today's and for Good Dan. Thanks, thank our company call excited the DefenCath the at and morning, CorMedix marks full as remain everyone. lead was as this I of the to
commercialization of NDA possible deficiencies until facility our potential that and as manufacturing supplier. of Unfortunately, ready satisfactory support CorMedix inspection made steps CMO X us as approval. FDA FDA critical CMO on progress they to diligently underwent Over fronts our the well as quickly last has the for DefenCath heparin of in all approved our cannot resolution as a announced at FDA at following Monday, informed months, be working undertaking the as company as multiple on a be the
While I'm another actions FDA heparin supplier well our complete the the adding CMO company multiple taking supplier. are support Give application as U.S., of of as Alcami I obtaining pathways and the disappointed existing a response letter toward approval the in we that in Heparin adding NDA. believe received and CMO the another
As the the fully date there time conducted original and of manner. a the and not explain inspection action will at responses CMO existing pre-approval between a was Phoebe inspection of in CMO our plans detail, to corrective in PDUFA to and thereof. the more obtain actions the August corrective full FDA's implement submitted timely FDA the sufficient XX and all and close verification CMO Unfortunately,
CRL deficiencies issued we side, implement API working are I PDUFA the fully am also or for to cited DefenCath to remediate issues corrective actions prior unable to the organizations Heparin clearing our and FDA obtain NDA no resubmission. a letter related were to for ahead, our the issues optimistic deficiencies to that the date. have both the way Notably, warning addition, unrelated to verification other and requirements remediate product. In potential aggressively although capability months these they ensuing FDA they approval the in for of a
with CMO is first to also of the as the prepared working early works resolve the it be CorMedix quarter to to commercialize the NDA, While resubmit deficiencies XXXX. as and
that name pending previously, with company In identified a a market approved another with addition, upon application application name our acceptability review. also been is agency product FDA the is has first. now trade had dependent the approved notified proposed under The which of trade although conditionally DefenCath has ultimate confusion potential the name
Center August DefenCath following technology Medicaid X conditional Services, per assumes an CorMedix or on precaution, of for to X, review. published new $X,XXX.XX proprietary stay hospital add-on catheter agency undergo already which the in a Register, commercial NTAP average standpoint, As the of utilized Federal CMS, has and or X reimbursement alternative payment DefenCath sessions. a the vials Medicare dialysis for we'll which name locks submitted for the Monday, From
derived in XXXX quarter following of FDA to and NDA be would the hospital inpatient call, from reimbursement per product the final X, an wholesale $X,XXX last The to upon As of charged we price discussed a hospital or prior effect on DefenCath approval calendar vial approval a the WAC earnings necessarily the the not cost gross July is NDA. institution conditioned ultimate drug reimbursement vial. NTAP NTAP first utilization price $X,XXX.XX take will to FDA of for WAC price is is obtaining the of of the list specific per of DefenCath and price acquisition net essentially pharmaceutical expected which and is the representative the a clinic.
setting setting expected higher. to price we only system, less outpatient health a reimbursement Due care the higher expect nature utilization utilization be is have net hospital of in have previously, As frequent where and to stated is we are required much to the have in the inpatient dialysis where lower in obtained to final to duplicate of we submit XXXX. preserve price our than care ability FDA CMS regardless one setting October NTAP but to X, setting July our net The in the this approval obtain each a price may be prior NTAP application WAC order of intends to not company be to different. to should new a
reimbursement. respect two-pronged specific to with is take to a approach NTAP our reimbursement, we outpatient inpatient to continue While
clinics. TDAPA secure First, outpatient as we allocated FDA is drug a service bundle transitional an or our to payment remain adjustment approval. anticipated payment to the by our efforts CMS after dialysis TDAPA renal incremental soon to to securing committed as practicable dialysis add-on
along to as CMS arguments a make betterment next Final few the over to utilization clinics compelling stakeholders of are statute of do sole other approval able DefenCath, CMS. fall patient we there with DefenCath clear, working believe these product before and a dialysis a the and systems, reimbursement formal to current decision and instances. believe While diligently the an arguments manufacturing. patient to key as is decision CMS the the over these any does To unique of discretion submission viable be approximately reimbursement CMS. will see to we required scope or we dialysis estimated better with unique under from for groups drug to advocacy DefenCath not to within but that in is will months, X to be hospital TDAPA from And affairs drive of calculated FDA utilize dialysis incentivizes such J-code. separately we Phoebe bundle a application J-code who the At reimbursed of this pathway and as and a outcomes. separately and the the update both an call I'd at ultimately the to reimburse separate time, part regulatory TDAPA TDAPA for timing application products to grant months is turn a J-code provide should Phoebe? be services unique like submit DefenCath are on by therefore, outpatient DefenCath We or operators of as product of
